We reviewed the incidence and risk factors for EBVrelated post-transplant lymphoproliferative disorder (EBV-PTLD) in 89 patients with acquired aplastic anaemia (AAA) receiving allogeneic transplants between 1989 and 2006. The overall incidence of EBV-PTLD was 6.3% (5/89) with no cases in those receiving an allograft for constitutional BM failure syndromes (n ¼ 30) during the same period. There was no impact of age, gender, donor status, CMV seropositivity, GVHD and graft cell dose on the occurrence of PTLD. Although both reduced intensity conditioning (RIC) and the prior use of antithymocyte globulin (ATG), as immunosuppressive therapy (IST), were identified as the risk factors for PTLD, only prior use of ATG strongly influenced the development of PTLD with an incidence of 13.38±5.6% (5/43), compared with none in those not exposed to ATG before transplantation (P ¼ 0.01) with a relative risk of 10.39 for each course of prior ATG. This is the first study in patients with AAA documenting that those receiving multiple prior courses of ATG are at the highest risk of developing EBV-PTLD.
Introduction
EBV-related post-transplant lymphoproliferative disorder (EBV-PTLD) is a serious and often fatal post-transplant complication, which has a widely variable incidence depending on several pre-and post-transplant factors including donor and recipient seropositivity, T-cell depletion, use of serotherapy, corticosteroids and GVHD. Most of the studies on PTLD have been based on the transplantation for malignant disorders or mixed underlying disorders. Unlike malignant diseases, where an allogeneic transplantation is invariably preceded by multiple courses of cytotoxic therapy, acquired aplastic anaemia (AAA) is a unique condition where transplantation is often preceded by immunosuppressive therapy (IST) with antithymocyte globulin (ATG) as the first-line therapy, particularly in older patients and even in younger patients without a family donor. We studied the incidence and risk factors for EBV-PTLD in patients with AAA, particularly in relation to previous IST and the nature of conditioning regimens.
Materials and methods
We retrospectively reviewed the incidence of EBV-PTLD in 87 consecutive patients undergoing 89 Allo-SCT for AAA at our institution between 1989 and 2006. Patients with constitutional aplastic anaemia (AA) were excluded. Conventional intensity conditioning was used for 76 transplants and consisted of a non-myeloablative CY dose of 200 mg/kg apart from two patients who received melphalan 140 mg/m 2 , in most cases with serotherapy (see below). Reduced intensity conditioning (RIC) was used in 13 patients and consisted of CY 1200 mg/m 2 , fludarabine 120 mg/m 2 and serotherapy with either Campath or ATG.
A total of 85 (95.5%) patients received serotherapy, in the form of either three doses of ATG (15 mg/kg Â 3 for horse ATG, lymphoglobulin; 3.75 mg/kg Â 3 for rabbit ATG, thymoglobuline, n ¼ 19, 21.3%) or five doses of Campath 0.2 mg/kg (n ¼ 66, 74.2%). Campath-1G was used before 1999, and Campath-1H (alemtuzumab) was used after 1998. GVHD prophylaxis consisted of CYA 2.5 mg/kg twice daily (1.25 mg/kg twice daily was used for those receiving itraconazole as antifungal prophylaxis), commencing day À1, and continued for at least 12 months to prevent secondary graft rejection. In addition, 22 (24.7%) patients received Campath in vivo post transplant. Unmanipulated BM was used for 76 (85.4%) transplants, whereas G-CSF mobilized PBSCs were used in seven (7.9%) transplants, and six (6.7%) patients received both BM and PBSC due to low nucleated cell counts from the BM harvest.
All patients were nursed in an high efficiency particulate air (HEPA) filtered room with standard antimicrobial prophylaxis as described previously.
1 EBV-PTLD was confirmed by radiological and/or histopathological evidence of lymphoproliferation with EBV confirmed either by PCR or immunohistochemistry.
Statistical analysis was performed using SPSS Version 12.0.1. The cumulative incidence of EBV-PTLD was calculated by Kaplan-Meier analysis, with factor comparison by the log-rank test. Univariate and multivariate relative hazards were calculated using Cox regression survival analysis. Incidence and outcome of EBV-PTLD EBV-PTLD occurred in five patients, with a cumulative incidence of 6.3±2.7%. No cases of EBV-PTLD were diagnosed in 30 patients transplanted for constitutional BM failure syndromes over the same time period. The clinical features, EBV viral loads and outcomes of patients experiencing EBV-PTLD are shown in Table 1 . Histological classification was high-grade diffuse large B cell or immunoblastic in all but one patient. Four patients survived following the withdrawal of immunosuppression, administration of donor lymphocyte infusion or treatment with rituximab. The lymphoproliferation was identified as of probable host origin based on molecular assessment of chimerism in all three patients evaluated. Overall survival was not significantly different in patients with or without PTLD (78.5±4.7% for patients without PTLD vs 80.0 ± 17.9% for patients with PTLD, P ¼ 0.95).
Results

Patients
Risk factors for EBV-PTLD
On univariate analysis of the potential risk factors for EBV-PTLD (Table 2) , there was no impact of age, gender, donor source, CMV seropositivity, time from diagnosis of AA to transplant, presence of acute GVHD or graft cell dose on the occurrence of EBV-PTLD. The type of serotherapy used in conditioning also did not have an influence, with EBV-PTLD developing in 1 out of 19 patients receiving ATG, and 4 out of 66 patients receiving However, prior use of ATG as IST for AAA had a strong influence on the development of EBV-PTLD. The cumulative incidence of EBV-PTLD in patients who received ATG before transplantation was 13.38 ± 5.6% (5 out of 43), compared to patients not exposed to ATG before transplantation (P ¼ 0.01, log-rank score). The total number of prior courses of ATG, also influenced the incidence of EBV-PTLD, with the cumulative incidence of EBV-PTLD was 4.4±4.3% in patients receiving one course of IST with ATG before Allo-SCT and the cumulative incidence in patients receiving two or more courses was 25.3±11%. This is described in Figure 1 , and the trend is statistically significant (P ¼ 0.002 by log-rank score with two degrees of freedom). On further Cox regression analysis, the relative risk of developing EBV-PTLD is 10.39 for each prior course of ATG (95% CI: 2.03-53.18, P ¼ 0.005, Cox regression).
Reduced-intensity conditioning also influenced the risk of developing EBV-PTLD with a relative risk of 8.8 (95% CI: 1.47-52.7, P ¼ 0.02, Cox regression analysis). The cumulative incidence of EBV-PTLD in patients receiving an RIC transplant was 23.9 ± 12% (3 out of 13), compared with 3.0 ± 2% (2 out of 76) for those receiving CIC (P ¼ 0.004, log-rank score). Use of fludarabine as part of the conditioning regimen did not significantly influence the relative hazard of developing EBV-PTLD in univariate Cox regression analysis. Interstingly, no PTLD was documented in patients suffering from constitutional AA who received an RIC, but no prior ATG.
When prior IST therapy with ATG and RIC were entered into a multivariate analysis for the risk of EBV-PTLD (Table 2) , RIC was no longer significantly associated with an increased relative hazard of EBV-PTLD, but prior ATG therapy remained significant. Although patients undergoing a matched unrelated donor transplant were more likely to have received two or more prior courses of ATG compared with patients receiving HLA identical sibling transplant (P ¼ 0.003, Fisher's exact test) on Cox regession analysis, donor source did not significantly influence the relative hazard of developing EBV-PTLD both on univariate analysis (Table 2) and in a multivariate model using both donor source and number of cycles of prior ATG.
Discussion
To the best of our knowledge, this is the first study on the incidence of PTLD in AAA patients who, unlike patients with malignant diseases, are not exposed to cytotoxic therapy before transplant, but are often exposed to prior ATG therapy. EBV reactivation has recently been shown to occur in 88-100% of EBV seropositive patients receiving ATG-based IST.
2 Although up to 60% of patients with AAA failing to respond to initial treatment with ATG or relapsing following therapy may respond to an additional course of ATG, 3 we have shown that increasing the number of courses of ATG therapy substantially increases the risk of EBV-PTLD for subsequent transplant procedures. Prior treatment with ATG and non-myeloablative conditioning, as employed in AAA, might play a role in the preferential survival of B-lymphocytes of host origin, creating a unique environment for host-derived EBV lymphoproliferation. 4 The unique effect of prior IST on EBV-PTLD is borne out by the absence of this condition in constitutional AA, where patients received RIC, but never received prior IST. EBV reactivation following ATG-based IST for AAA has been shown to achieve both high peaks as well as low level persistence. 2 The recent study from the National Institutes of Health suggested that the use of rabbit ATG was associated with a higher EBV load. No such pattern was seen in our study. However, the EBV lymphoproliferative disorder has not been documented in this setting. Intensive and selective T-cell depletion by multiple courses of ATG might create a unique environment for unabated EBV replication in the pre-transplant period, which translates to EBV-PTLD in the post-transplant period. Donor-derived EBV-cytotoxic T lymphocyte (CTL) recovery is possibly much more protracted in the face of serotherapy-based conditioning than autologous CTL recovery following IST.
Use of Campath at high doses might protect against EBV-LPD because of the concomitant depletion of B cells in other conditions, 5 but does not seem to have a similar effect, at least in this group of patients, who have received several courses of ATG-based IST before the allograft. Moreover, Campath-1H-based serotherapy has been shown to delay the recovery of EBV-specific CTL beyond 6 to 9 months. 4 Untreated, EBV-PTLD has a high mortality, 6 but early recognition and treatment by withdrawal of immunsuppression and rituximab improves the outcome. [7] [8] [9] The appropriate threshold for initiation of therapy remains to be established. However, rather than a single value, the dynamics of the viral load should dictate the necessity for intervention. We have initiated routine monitoring of EBV viral load in the pre-and post-transplant period in all such patients. Our study has documented for the first time that patients who have received multiple courses of ATG are deemed to be at the highest risk for development of PTLD, and careful consideration should be given to the EBV load pre-transplant and the conditioning schedule.
